Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novel Database Unifies the Knowledge of 100 Years of Drug Research

Published: Friday, November 09, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
More than 5000 scientific publications on clinical trials in humans and preclinical animal trials concerning the bioavailability of drugs have been evaluated.

PharmaInformatic has developed a comprehensive knowledge base on bioavailability, which enables the targeted development of new drugs.

Several factors affect the oral bioavailability of drugs. For the first time, these can now be analyzed in detail, thanks to a new resource.

The new resource, called PACT-F (Preclinical And Clinical Trials Knowledge Base on Bioavailability) unifies the results and experiences of the last hundred years of drug research.

The development of the knowledge base began in 2005. Since then the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database.

Each of the 8296 records contains the chemical structure of the investigated drug and up to 17 additional fields, which describe in detail the experimental conditions of the trials (gender, age, health status and number of subjects, genetic differences, the species examined, route of administration, additional medication, method of measurement, drug formulation and further descriptions of the studies).

The knowledge base is a fundamental tool to develop computer models, which can predict the oral bioavailability of new drugs in humans, before clinical trials have to be conducted.

This increases the prospects of new drugs and enhances the safety of clinical trials in humans.

Dr Wolfgang Boomgaarden, founder and CEO of PharmaInformatic, says, 'Our research is a huge step forward in the area of drug development and will improve the efficiency of clinical trials in humans. Fundamental new findings and conclusions can be derived from the knowledge base which will impact future drug discovery and development.'

Oral bioavailability is one of the most important properties of a drug.

If a new drug candidate has low or no oral bioavailability, further drug development will be stopped, because the candidate cannot be absorbed in the body.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Friday, September 12, 2014
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!